A tunable genome editing system of the prime editor mediated by dihydrofolate reductase

Shu Liu; Xiaoyue Duan; Feng Peng; Yafang Wang; Yang Liu; Xiaoling Wan; Jingfa Zhang; Xiaosa Li; Xiaodong Sun

doi:10.1016/j.jgg.2022.08.004

Volume 50 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Genetics and Genomics > 2023 > 50(3): 204-207

PDF( 1074 KB)

A tunable genome editing system of the prime editor mediated by dihydrofolate reductase

doi: 10.1016/j.jgg.2022.08.004

1. Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China;
2. Department of Ophthalmology, Shanghai Changhai Hospital, Shanghai 200043, China;
3. Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China;
4. Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China;
5. Shanghai Key Laboratory of Ocular Fundus Diseases, 100 Haining Road, Shanghai 200080, China

Funds:

The authors thank Jia Chen for the assistance at Gene Editing Center, School of Life Science and Technology, ShanghaiTech University for providing experimental service. This research was surported by Research Foundation of Shanghai General Hospital.

Received Date: 2022-05-18
Accepted Date: 2022-08-22
Rev Recd Date: 2022-08-19
Publish Date: 2022-08-30

Abstract

FullText(HTML)

References(20)

References

[1]	An, X., Li, L., Wu, S., 2019. In vivo tunable CRISPR mediates efficient somatic mutagenesis to generate tumor models. Protein Cell 10, 450-454.
[2]	Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L.W., Levy, J.M., Chen, P.,J., Wilson, C., Newby, G.A., Raguram, A., et al., 2019. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149-157.
[3]	Banaszynski, L.A., Chen, L.C., Maynard-Smith, L.A., Ooi, A.G., Wandless, T.J., 2006. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995-1004.
[4]	Barling, R.W., Selkon, J.B., 1978. The penetration of antibiotics into cerebrospinal fluid and brain tissue. J. Antimicrob. Chemother. 4, 203-227.
[5]	Barrangou, R., Fremaux, C.,Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., Horvath, P., 2007. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709-1712.
[6]	Charlesworth, C.T., Deshpande, P.S., Dever, D.P., Camarena, J., Lemgart, V.T., Cromer, M.K., Vakulskas, C. A., Collingwood, M.A., Zhang, L., Bode, N.M., et al., 2019. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249-254.
[7]	Chen, J., Lin, F.L., Leung, J.Y.K., Tu, L., Wang, J.H., Chuang, Y.F., Li, F., Shen, H.H., Dusting, G.J., Wong, V.H.Y., et al., 2021. A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization. Angiogenesis 24, 97-110.
[8]	Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., et al., 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823.
[9]	Datta, S., Renwick, M., Chau, V.Q., Zhang, F., Nettesheim, E.R., Lipinski, D.M., Hulleman, J.D., 2018. A destabilizing domain allows for fast, noninvasive, conditional control of protein abundance in the mouse eye - implications for ocular gene therapy. Invest. Ophthalmol. Vis. Sci. 59, 4909-4920.
[10]	Jiang, Y.Y., Chai, Y.P., Lu, M.H., Han, X.L., Lin, Q., Zhang, Y., Zhang, Q., Zhou, Y., Wang, X.C., Gao, C., et al., 2020. Prime editing efficiently generates W542L and S621I double mutations in two ALS genes in maize. Genome Biol. 21, 257.
[11]	Liu, P., Liang, S.Q., Zheng, C., Mintzer, E., Zhao, Y.G., Ponnienselvan, K., Mir, A., Sontheimer, E.J., Gao, G., Flotte, T.R., et al., 2021. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121.
[12]	Oeemig, J.S., Aranko, A.S., Djupsjobacka, J., Heinamaki, K., Iwai, H., 2009. Solution structure of DnaE intein from Nostoc punctiforme: structural basis for the design of a new split intein suitable for site-specific chemical modification. FEBS Lett. 583, 1451-1456.
[13]	Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K.M., Gregg, A., Noggle, S., Tessier-Lavigne, M., 2016. Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. Nature 533, 125-129.
[14]	Schene, I.F., Joore, I.P., Oka, R., Mokry, M., van, Vugt, A.H.M., van, Boxtel, R., van, der, Doef, H.P.J., vander, Laan, L.J.W., Verstegen, M.M.A., van, Hasselt, P.M., et al., 2020. Prime editing for functional repair in patient-derived disease models. Nat. Commun. 11, 5352.
[15]	Schweitzer, B.I.D.A.P., Bertino, J.R., 1990. Dihydrofolate reductase as a therapeutic target. Faseb. J. 4, 2441-2452.
[16]	Sellmyer, M.A., Chen, L.C., Egeler, E.L., Rakhit, R., Wandless, T.J., 2012. Intracellular context affects levels of a chemically dependent destabilizing domain. PLoS One 7, e43297.
[17]	Shah, N.H., Vila-Perello, M., Muir, T.W., 2011. Kinetic control of one-pot trans-splicing reactions by using a wild-type and designed split intein. Angew. Chem., Int. Ed. Engl. 50, 6511-6515.
[18]	Vithana, E.N., Abu-Safieh, L., Allen, M.J., Carey, A., Papaioannou, M., Chakarova, C., Al-Maghtheh, M., Ebenezer, N.D., Willis, C., Moore, A.T., et al., 2001. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol. Cell 8, 375-381.
[19]	Wagner, D.L., Amini, L., Wendering, D.J., Burkhardt, L.M., Akyuz, L., Reinke, P., Volk, H.D., Schmueck-Henneresse, M., 2019. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med. 25, 242-248.
[20]	Waseem, N.H., Vaclavik, V., Webster, A., Jenkins, S.A., Bird, A.C., Bhattacharya, S.S., 2007. Mutations in the gene coding for the pre-mRNA splicing factor, PRPF31, in patients with autosomal dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 48, 1330-1334.